EGFR and head and neck cancer: Targeted therapy in head and neck cancer is closely connected to the use of cetuximab, an anti-Epidermal Growth Factor Receptor (EGFR) antibody therapy, confirmed to be effective in combination with radiotherapy in previously untreated patients in a single controlled clinical trial [46,47].